Synergistic effects of multicomponent exercise and rTMS on sarcopenia and mild cognitive impairment in older people: a protocol for a randomized controlled trial Authors: Yanqing Ren, Xiangfeng He, Zhen Zhang, Min Zhuang, Gonghua Yin, Lingyan Huang, Nan Chen Published: 2025 ABSTRACT AbstractBackgroundSarcopenia and cognitive impairment (CI) are major contributors to disability in older people, significantly reducing quality of life and imposing a substantial burden on healthcare systems. Sarcopenia accelerates cognitive decline through mechanisms such as chronic inflammation, mitochondrial dysfunction, and disruption of the muscle–brain axis. Conversely, CI impairs motor planning and daily functioning, further exacerbating muscle loss and physical deterioration. Previous studies have shown that physical exercise optimizes peripheral physiological conditions, promoting neuroplasticity in the central nervous system. Similarly, repetitive transcranial magnetic stimulation (rTMS) enhances brain plasticity, improving both cognitive and physical functions. This study aims to evaluate the combined effects of multicomponent exercise and rTMS on sarcopenia and CI in older people.MethodsThis is a 16-week, randomized, single-blind, controlled trial. A total of 51 older people with sarcopenia and mild cognitive impairment (MCI) will be randomly assigned to one of three groups: (1) exercise combined with rTMS, (2) exercise combined with sham rTMS, and (3) a control group. The exercise intervention will integrate Baduanjin and resistance training, while rTMS will target the dorsolateral prefrontal cortex (DLPFC). Participants will be assessed for muscle fitness, cognitive function, and psychological well-being at baseline, week 8, and week 16.DiscussionThis trial aims to provide empirical evidence on the synergistic effects of exercise and rTMS in managing sarcopenia and MCI in older people. Additionally, it will explore the neural mechanisms underlying improvements in cognitive function. The findings may inform integrated treatment strategies for these interconnected conditions, enhancing quality of life and promoting functional independence in aging populations.Trial registrationInternational Traditional Medicine Clinical Trial Registry, ITMCTR2025000311. Registered 17 February 2025.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12877-025-06876-8.Keywords: Sarcopenia, Mild cognitive impairment, Baduanjin, Resistance exercise, Transcranial magnetic stimulation Introduction Sarcopenia, an age-related geriatric syndrome, is characterized by a significant decline in muscle mass, muscle strength, and physical performance [1]. It increases the risk of falls and fractures [2] and is closely associated with various chronic conditions, including cognitive impairment [3], cardiovascular diseases [4], and depression [5]. The prevalence of sarcopenia is 5%−13% in individuals aged 60–70 years, and 11%−50% in those aged 80 and above [6]. Cognitive impairment primarily includes mild cognitive impairment (MCI) and dementia [7]. MCI is a transitional stage between age-related cognitive decline and dementia [8], with a substantially increased risk of progression to dementia [9, 10]. Studies indicate that over 50% of individuals with MCI may develop dementia within 4 to 6 years [9], and the risk of dementia in individuals with MCI is approximately 10-fold higher compared to cognitively normal peers [10]. With the aging of the global population, both two conditions have become major public health challenges [11, 12]. Emerging epidemiological evidence reveals bidirectional links between sarcopenia and CI. A cross-sectional study involving individuals aged 60 and above revealed significantly worse cognitive performance in sarcopenic individuals, particularly in orientation, calculation, memory, and visuospatial abilities, compared to their non-sarcopenic counterparts [3]. A 5.6-year longitudinal study further confirmed that baseline sarcopenia severity predicted both higher incidence of MCI and accelerated cognitive decline [13]. Conversely, CI may precede sarcopenia, as evidenced by Pacifico et al. ‘s finding of threefold higher sarcopenia prevalence in dementia patients (26.4%) versus controls (8.4%) [14]. Although the exact mechanisms linking sarcopenia and CI remain unclear, emerging studies suggest that chronic inflammation, mitochondrial oxidative stress, and alterations in the muscle-brain axis may play critical roles [15]. Specifically in Alzheimer’s disease (AD), Aβ-induced glial activation drives neuroinflammation and oxidative stress, reducing brain-derived neurotrophic factor (BDNF) circulation and promoting sarcopenia pathogenesis. Conversely, sarcopenia exacerbates systemic inflammation and impairs myokine secretion (e.g., BDNF, irisin), which further disrupts neuronal homeostasis and accelerates AD progression. This reciprocal crosstalk establishes a self-reinforcing vicious cycle between neuromuscular degeneration and cognitive decline [16]. Early intervention for both sarcopenia and CI may therefore help mitigate disability progression in aging populations. Physical activity elevates circulating myokines—including insulin-like growth factor-1 (IGF-1) and BDNF—which enhance neurocognitive function by regulating neuronal proliferation, differentiation, synaptic plasticity, and memory consolidation [17]. Although exercise modulates peripheral neural pathways to induce muscular adaptation [18], this mechanism provides insufficient neurocognitive benefits for older people with sarcopenia and comorbid CI. Repetitive transcranial magnetic stimulation (rTMS), a non-invasive neuromodulation technique [19], augments cortical plasticity to facilitate motor recovery [20, 21]. Crucially, by enhancing neural plasticity and neural network functionality [22, 23], rTMS synergistically potentiates exercise-induced therapeutic outcomes and improves cognitive-motor integration. However, this combined strategy has not been explored in older people with sarcopenia and cognitive impairment. Therefore, the aim of this study is to implement a combined intervention strategies integrating multicomponent exercise and rTMS to manage sarcopenia and delay the progression of CI in older people and to investigate the underlying neurophysiological mechanisms. Methods Study design This study is a randomized, single-blind, clinically controlled trial conducted from March 2025 to January 2026 at community health service centers in Shanghai, China. Eligible participants will be randomly assigned to one of three groups in a 1:1:1 ratio: the multicomponent exercise with active rTMS (Ex + rTMS) group, the multicomponent exercise with sham rTMS (Ex + Sham-rTMS) group, and the control group. At baseline, demographic information including age, sex, education, comorbidities, current medication use, and alcohol and smoking status will be collected. Cognitive function and sarcopenia-related outcomes will be assessed at baseline, post-intervention, and follow-up. Additionally, functional near-infrared spectroscopy (fNIRS) will be used to measure brain activation and connectivity, providing insights into the mechanisms underlying cognitive improvement. During the 8-week intervention period, participants’ physical activity levels and dietary status will be monitored using the International Physical Activity Questionnaire (IPAQ) [24] and the Food Frequency Questionnaire (FFQ) [25], respectively. The timetable for recruitment, assessment, and intervention is shown in Table 1. The flowchart for this study is shown in Fig. 1. The 2013 Standard Protocol Items for Randomized Trials checklist is available in Additional file 1. This study was registered on the International Traditional Medicine Clinical Trial Registry, with registration number ITMCTR2025000311. Table 1Schedule of recruitment, interventions and assessmentsMeasurementBeforeBaseline(week 0)Post-intervention(week 8)Follow-up(week 16)Enrollment Recruitment and screeningX Inclusion and exclusion criteriaX Information consentXRandomized allocationXIntervention Repetitive Transcranial Magnetic StimulationX Sham stimulationX Multicomponent exerciseXDemographics Demographics informationX Comorbid Illnesses and concomitant medicationsX Tea, alcohol intake, smoking statusXPrimary outcomes assessments Montreal Cognitive Assessment (MoCA)XXX Handgrip strengthXXXSecondary outcomes assessments Wechsler Memory Scale-Revised for China (WMS-RC)XXX Victoria Stroop Test (VST)XXX Trail Making Test Part B (TMT-B)XXX Muscle massXXX Knee extension strengthXXX Physical performanceXXX Geriatric Depression Scale-15 (GDS-15)XXX Near-infrared spectroscopyXXXMonitoring indicators International Physical Activity Questionnaire (IPAQ)XXX Food Frequency Questionnaire (FFQ)XXXSafety and Compliance Participants’ complianceXX Adverse eventsXX Reasons for dropoutXX Schedule of recruitment, interventions and assessments Study flow diagram. Abbreviations: SARC-F, Strength, Assistance with walking, Rise from a chair, Climb stairs, and Falls questionnaire; MMSE, Mini-Mental State Examination; Ex + rTMS, Combined exercise with active repetitive transcranial magnetic stimulation; Ex + Sham- rTMS, Combined exercise with sham repetitive transcranial magnetic stimulation; rTMS, Repetitive Transcranial Magnetic Stimulation; DLPFC, Dorsolateral prefrontal cortex; ASMI, Appendicular Skeletal Muscle Mass Index; HGS, Handgrip Strength; KES, Knee Extension Strength; SPPB, Short Physical Performance Battery; MoCA, Montreal Cognitive Assessment; VST, Victoria Stroop Test; TMT-B, Trail Making Test Part B; GDS-15, Geriatric Depression Scale-15 items Participants Diagnostic criteria The diagnostic criteria of sarcopenia refer to the Asian Working Group for Sarcopenia 2019 criteria (AWGS 2019) [26]:① Appendicular skeletal muscle mass index (ASMI) < 7.0 kg/m² for men and < 5.7 kg/m² for women; and② Handgrip strength (HGS) is < 28 kg for men and < 18 kg for women; and/or③ 6-m gait speed (GS) is < 1 m/s. The diagnostic criteria of sarcopenia refer to the Asian Working Group for Sarcopenia 2019 criteria (AWGS 2019) [26]: ① Appendicular skeletal muscle mass index (ASMI) < 7.0 kg/m² for men and < 5.7 kg/m² for women; and ② Handgrip strength (HGS) is < 28 kg for men and < 18 kg for women; and/or ③ 6-m gait speed (GS) is < 1 m/s. The diagnostic criteria of MCI are based on to the 2004 Petersen MCI diagnostic criteria [27]:① Subjective cognitive decline: Reported by the participant or an informant, indicating perceived deterioration in cognitive function over the past two years.② Objective cognitive impairment: Performance on at least one cognitive subtest more than one standard deviation (SD) below the age- and education-adjusted norm (i.e., age- and education-specific z-scores), or a score of ≥ 3 on the clock-drawing test. The cognitive domains assessed include immediate and delayed verbal memory (eight-word list), problem-solving and processing speed (labyrinth test), verbal fluency (animal naming within 1 min), and executive as well as visuospatial function (clock-drawing test).③ Preserved basic activities of daily living.④ No dementia, defined as not meeting DSM-IV criteria for dementia. The diagnostic criteria of MCI are based on to the 2004 Petersen MCI diagnostic criteria [27]: ① Subjective cognitive decline: Reported by the participant or an informant, indicating perceived deterioration in cognitive function over the past two years. ② Objective cognitive impairment: Performance on at least one cognitive subtest more than one standard deviation (SD) below the age- and education-adjusted norm (i.e., age- and education-specific z-scores), or a score of ≥ 3 on the clock-drawing test. The cognitive domains assessed include immediate and delayed verbal memory (eight-word list), problem-solving and processing speed (labyrinth test), verbal fluency (animal naming within 1 min), and executive as well as visuospatial function (clock-drawing test). ③ Preserved basic activities of daily living. ④ No dementia, defined as not meeting DSM-IV criteria for dementia. Inclusion criteria Participants will be eligible for inclusion if they meet all of the following criteria: Aged 60 years or older; Aged 60 years or older; Diagnosed with both sarcopenia and MCI; Diagnosed with both sarcopenia and MCI; Lack of regular physical activity, defined as engaging in ≥ 20 min of vigorous-intensity exercise on at least 3 days per week, or ≥ 30 min of moderate-intensity exercise on at least 5 days per week, as per established guidelines [28]; Lack of regular physical activity, defined as engaging in ≥ 20 min of vigorous-intensity exercise on at least 3 days per week, or ≥ 30 min of moderate-intensity exercise on at least 5 days per week, as per established guidelines [28]; Sufficient cognitive and communicative ability to comprehend study procedures and provide written informed consent. Sufficient cognitive and communicative ability to comprehend study procedures and provide written informed consent. Exclusion criteria Participants will be excluded if they meet any of the following conditions: Inability to comply with the exercise protocol due to motor dysfunction resulting from neurological disorders, musculoskeletal conditions, severe organ diseases, or any other contraindications to physical activity; Inability to comply with the exercise protocol due to motor dysfunction resulting from neurological disorders, musculoskeletal conditions, severe organ diseases, or any other contraindications to physical activity; A score ≥ 9 on the geriatric depression scale-15 (GDS-15); A score ≥ 9 on the geriatric depression scale-15 (GDS-15); Regular use of medications within the past three months that may influence motor or cognitive function, including but not limited to: antiplatelet agents, anticoagulants, analgesics, antihypertensive drugs, lipid-lowering agents, antipsychotic medications, or high-dose corticosteroids; Regular use of medications within the past three months that may influence motor or cognitive function, including but not limited to: antiplatelet agents, anticoagulants, analgesics, antihypertensive drugs, lipid-lowering agents, antipsychotic medications, or high-dose corticosteroids; Contraindications to rTMS or fNIRS, such as a history of epilepsy, brain tumors, cerebral aneurysms, encephalitis, acute brain injury, or other cerebrovascular diseases; or the presence of severe scalp rashes or infections, excessive scalp thickness or subcutaneous fat, or any implanted metal devices or electronic implants; Contraindications to rTMS or fNIRS, such as a history of epilepsy, brain tumors, cerebral aneurysms, encephalitis, acute brain injury, or other cerebrovascular diseases; or the presence of severe scalp rashes or infections, excessive scalp thickness or subcutaneous fat, or any implanted metal devices or electronic implants; Receipt of rTMS or transcranial direct current stimulation (tDCS) within two weeks prior to enrollment; Receipt of rTMS or transcranial direct current stimulation (tDCS) within two weeks prior to enrollment; Current participation in other clinical trials that may interfere with this study. Current participation in other clinical trials that may interfere with this study. Termination criteria Participants will be terminated from the study if any of the following conditions are met: Voluntary withdrawal from the study at any time; Voluntary withdrawal from the study at any time; Occurrence of serious adverse events related to the intervention that prevent continued participation; Occurrence of serious adverse events related to the intervention that prevent continued participation; Failure to comply with the intervention protocol; Failure to comply with the intervention protocol; Loss to follow-up during the intervention or follow-up period. Loss to follow-up during the intervention or follow-up period. Sample size Sample size estimation was performed using G*Power 3.1. Effect sizes were derived from previous meta-analyses on rTMS and exercise interventions targeting sarcopenia and cognitive impairment. Reported effect sizes included: rTMS on muscle strength (Cohen’s d = 0.66) [29], combined exercise on knee extension strength (d = 0.62) [30], and active rTMS on cognitive function (Cohen’s d = 0.48) [31]. To provide a conservative estimate, the smallest effect size (Cohen’s d = 0.48) was selected. The corresponding Cohen’s f = 0.24 was calculated using the formula. With α = 0.05 and power (1 − β) = 0.80, the repeated-measures ANOVA (within–between interaction) indicated that 39 participants in total were required. Allowing for a 20% dropout rate and maintaining a strict 1:1:1 allocation, we will recruit 51 participants in total (17 per group). Randomization and masking Fifty-one eligible participants will be randomly assigned to one of three groups (Ex + rTMS, Ex + Sham-rTMS, and control) in a 1:1:1 ratio. Randomization will be conducted using a stratified block randomization procedure with a fixed block size of six [32], generated by an independent statistician (not involved in the study) with SPSS version 27 (SPSS, Inc.), stratified by gender and age to ensure balance in key demographic characteristics. Allocation concealment will be maintained using sequentially numbered, opaque, sealed envelopes (SNOSE) prepared by the independent statistician. Each envelope will contain the participant’s group code and will be opened sequentially after baseline assessment by a research coordinator who is not involved in data collection or analysis [33]. The randomization and group assignment data will be securely encrypted and stored in an electronic database managed by external researchers. Therapists will deliver interventions according to the respective group protocols. Statisticians, assessors, and data managers will be blinded to group assignments. Masking will be removed in the event of a medical emergency requiring immediate intervention, with the approval of the responsible investigator and the knowledge of the data monitoring committee (DMC). Unblinding will only occur under these circumstances to ensure the participant’s safety, and the procedure will follow a standardized protocol. All unblinding events will be documented and reported to the ethics committee within 24 hours [34]. Recruitment Participant recruitment will take place from March 2025 to January 2026 in selected towns within Shanghai, China. A multifaceted recruitment strategy will be implemented. First, annual health screenings will be conducted in designated communities to identify eligible residents. Educational lectures on sarcopenia and CI will be delivered to enhance public awareness and attract potential participants. Home visits will be arranged in collaboration with community staff to engage older people who do not regularly attend health screenings. Additionally, research announcements will be posted on community bulletin boards to further promote enrollment. Screening All potential participants will complete the Strength, Assistance with walking, Rise from a chair, Climb stairs, and Falls (SARC-F) questionnaire, along with the Mini-Mental State Examination (MMSE). Individuals scoring ≥ 4 on the SARC-F and < 24 on the MMSE will be further assessed for eligibility based on the study’s inclusion and exclusion criteria. Intervention Intervention duration The 16-week intervention, consisting of 8 weeks of supervised training and 8 weeks of home-based follow-up, will be designed based on previous evidence regarding the temporal dynamics of neuroplastic and functional adaptations induced by exercise and rTMS. Randomized controlled trials have shown that 2–6 weeks of high-frequency rTMS (typically 10–30 sessions) can significantly improve global cognition or specific cognitive domains in individuals with MCI and Alzheimer’s disease [35, 36], with some studies reporting sustained effects at one-month follow-up [37]. These improvements are attributed to the induction of long-term potentiation (LTP)-like neuroplasticity, which requires repeated stimulation over several weeks for stable consolidation. For multicomponent exercise interventions, 8–12 weeks of training have been shown to significantly enhance muscle strength, cognitive performance, and overall physical function in older adults [30, 38]. Furthermore, combined neuromodulation–exercise protocols are expected to require sufficient duration for rTMS-induced neural priming and exercise-driven neuroplastic adaptations to interact synergistically [39]. Based on this evidence, the present study will implement an 8-week intensive supervised phase to induce peak neuroplastic responses, followed by an 8-week home-based phase to consolidate these gains and evaluate their sustainability. Group protocols All interventions will last 8 weeks, with three sessions per week. Each intervention consists of two components: first, participants in the Ex + rTMS group will receive 20 min of active rTMS, while the other two groups will receive sham stimulation. Then, the Ex + rTMS and Ex + Sham-rTMS groups will engage in a 45-minute Baduanjin and resistance training (BDJ-RT) program, while the control group will attend a 45-minute health education course on sarcopenia and CI. All rTMS or sham stimulation will be administered by licensed rehabilitation therapists with at least three years of clinical experience in neurorehabilitation and formal certification in transcranial magnetic stimulation (TMS) operation. The BDJ-RT sessions will be led by exercise coaches certified by the Chinese Health Qigong Association and trained in geriatric exercise instruction to ensure safety and standardization. Pre-InterventionBefore the exercise intervention begins, all participants will undergo a one-repetition maximum (1RM) test to assess maximal strength and use the Borg Category Ratio (CR10) Rating of Perceived Exertion (RPE) scale to determine target load. To standardize exercise intensity, the TheraBand force-elongation table will guide the selection of resistance bands. Participants will also receive three structured Baduanjin instruction sessions to ensure proper movement and posture.For rTMS preparation, the resting motor threshold (RMT) will be determined by locating the primary motor cortex (M1) and adjusting the stimulation position until clear motor evoked potentials (MEPs) are induced in the contralateral muscles. The minimum intensity required to elicit this response will define the RMT. Pre-Intervention Before the exercise intervention begins, all participants will undergo a one-repetition maximum (1RM) test to assess maximal strength and use the Borg Category Ratio (CR10) Rating of Perceived Exertion (RPE) scale to determine target load. To standardize exercise intensity, the TheraBand force-elongation table will guide the selection of resistance bands. Participants will also receive three structured Baduanjin instruction sessions to ensure proper movement and posture. For rTMS preparation, the resting motor threshold (RMT) will be determined by locating the primary motor cortex (M1) and adjusting the stimulation position until clear motor evoked potentials (MEPs) are induced in the contralateral muscles. The minimum intensity required to elicit this response will define the RMT. During the InterventionDuring the 8-week intervention, real-time RPE scores will be collected to monitor and adjust exercise intensity. Participants will be encouraged to maintain an exertion level of 5–7 (“moderate to somewhat hard”). If fatigue, discomfort, or an RPE score >7 is reported, the exercise intensity or duration will be reduced according to the participant’s tolerance and feedback [40]. Attendance will be recorded at each session, and missed sessions will be rescheduled within the same week.For rTMS, if participants experience significant scalp discomfort, pain, or dizziness during stimulation, the intensity will be gradually reduced until symptoms subside; stimulation may be temporarily paused if necessary [41].Any adverse events will be documented and reviewed by the study physician to ensure participant safety. During the Intervention During the 8-week intervention, real-time RPE scores will be collected to monitor and adjust exercise intensity. Participants will be encouraged to maintain an exertion level of 5–7 (“moderate to somewhat hard”). If fatigue, discomfort, or an RPE score >7 is reported, the exercise intensity or duration will be reduced according to the participant’s tolerance and feedback [40]. Attendance will be recorded at each session, and missed sessions will be rescheduled within the same week. For rTMS, if participants experience significant scalp discomfort, pain, or dizziness during stimulation, the intensity will be gradually reduced until symptoms subside; stimulation may be temporarily paused if necessary [41]. Any adverse events will be documented and reviewed by the study physician to ensure participant safety. Post-InterventionAfter completing the intervention, participants will be encouraged to continue BDJ and resistance training at home. Written and video-based instructional materials will be provided to support long-term adherence and consolidation of physical and cognitive gains. Post-Intervention After completing the intervention, participants will be encouraged to continue BDJ and resistance training at home. Written and video-based instructional materials will be provided to support long-term adherence and consolidation of physical and cognitive gains. Exercise program All exercise procedures will be standardized and implemented according to established guidelines to ensure reproducibility. Specifically, the “Health Qigong–Baduanjin” guidelines published by the General Administration of Sport of China (2003) will be followed for the Baduanjin exercise component [42]. The progressive resistance training protocol will be designed based on the guidelines provided by the American College of Sports Medicine for resistance training in older adults [43]. Warm-up exercises (5 minutes)The warm-up exercises will consist of two parts. The first part includes joint mobility exercises, targeting movements in various directions for the neck, lower back, shoulder joints, knee joints, and ankle joints. The second part involves slow, controlled stretching exercises targeting major muscle groups such as the quadriceps, calves, and latissimus dorsi. Warm-up exercises (5 minutes) The warm-up exercises will consist of two parts. The first part includes joint mobility exercises, targeting movements in various directions for the neck, lower back, shoulder joints, knee joints, and ankle joints. The second part involves slow, controlled stretching exercises targeting major muscle groups such as the quadriceps, calves, and latissimus dorsi. Baduanjin exercise (15 minutes)Participants will perform a sequence of eight movements, each repeated twice: prop both hands to the sky, draw a bow on both sides as if shooting a vulture, raise a single arm, look back, sway the head and shake the tail, clench fists and push forward with focus, touch toes by hands with flexion of hip and extension of knee joint, and rise and bounce on the toes. Baduanjin exercise (15 minutes) Participants will perform a sequence of eight movements, each repeated twice: prop both hands to the sky, draw a bow on both sides as if shooting a vulture, raise a single arm, look back, sway the head and shake the tail, clench fists and push forward with focus, touch toes by hands with flexion of hip and extension of knee joint, and rise and bounce on the toes. Resistance training (20 minutes)Participants will use elastic bands to perform a series of upper and lower body resistance training, including shoulder abduction and adduction, elbow flexion and extension, hip flexion and extension, and knee flexion and extension. Each movement will be held for 3 s and performed in 2 sets of 10 repetitions, with a 30-second rest between sets. The training intensity will be adjusted using color-coded elastic bands: 60% of 1RM during weeks 1–4 and, 65% of 1RM during weeks 5–8. Resistance training (20 minutes) Participants will use elastic bands to perform a series of upper and lower body resistance training, including shoulder abduction and adduction, elbow flexion and extension, hip flexion and extension, and knee flexion and extension. Each movement will be held for 3 s and performed in 2 sets of 10 repetitions, with a 30-second rest between sets. The training intensity will be adjusted using color-coded elastic bands: 60% of 1RM during weeks 1–4 and, 65% of 1RM during weeks 5–8. Relaxation exercises (5 minutes)The relaxation exercises will repeat the warm-up exercises, including joint mobility and stretching exercises. Relaxation exercises (5 minutes) The relaxation exercises will repeat the warm-up exercises, including joint mobility and stretching exercises. rTMS The rTMS procedure will be conducted in accordance with the 2014 International Guidelines for Repetitive Transcranial Magnetic Stimulation Treatment [44]. rTMS will be delivered using a MagTD stimulator (Wuhan, China) equipped with a 90-mm figure-of-eight coil. The stimulation target will be the left dorsolateral prefrontal cortex (DLPFC), localized according to the 5 cm rule by identifying a site 5 cm anterior and 2 cm lateral to the motor hotspot (M1). Stimulation parameters will include a frequency of 10 Hz and an intensity set at 90% of the RMT, with each session comprising 2,000 pulses (40 pulses per train, 50 trains). Each session will last approximately 20 min. During sham stimulation, the coil will be rotated 90° and positioned perpendicular to the scalp to effectively prevent magnetic field induction, while all other stimulation parameters will remain identical to those in the active condition. Participants will wear earplugs throughout the procedure to minimize auditory input, and any adverse events will be closely monitored to ensure safety and tolerability. Outcomes Primary outcomes Cognitive functionGlobal cognitive function will be assessed using the Montreal Cognitive Assessment (MoCA) [45], a standardized instrument that evaluates eight cognitive domains: visuospatial/executive function, naming, memory, attention, language, abstraction, delayed recall, and orientation. The total score ranges from 0 to 30, with higher scores indicating better cognitive performance. To adjust for education, one point will be added for participants with 12 or fewer years of formal education. A total score below 26 will be considered indicative of MCI. Cognitive function Global cognitive function will be assessed using the Montreal Cognitive Assessment (MoCA) [45], a standardized instrument that evaluates eight cognitive domains: visuospatial/executive function, naming, memory, attention, language, abstraction, delayed recall, and orientation. The total score ranges from 0 to 30, with higher scores indicating better cognitive performance. To adjust for education, one point will be added for participants with 12 or fewer years of formal education. A total score below 26 will be considered indicative of MCI. Handgrip strengthHGS, an indicator of limb muscle strength, will be measured using a grip dynamometer (Digital Hand Dynamometer Jamar Plus+; IL, USA). Participants will sit and hold the dynamometer in their dominant hand, with the upper limb abducted at a 30-degree angle from their body. They will apply maximum force for at least 5 s until a stable reading is reached [46]. This process will be repeated three times with 30-second intervals, and the highest value will be recorded as the final HGS. Handgrip strength HGS, an indicator of limb muscle strength, will be measured using a grip dynamometer (Digital Hand Dynamometer Jamar Plus+; IL, USA). Participants will sit and hold the dynamometer in their dominant hand, with the upper limb abducted at a 30-degree angle from their body. They will apply maximum force for at least 5 s until a stable reading is reached [46]. This process will be repeated three times with 30-second intervals, and the highest value will be recorded as the final HGS. Secondary outcomes Memory functionThe Wechsler Memory Scale-Revised for China (WMS-RC) is a standardized and widely implemented instrument for evaluating comprehensive memory function [47]. It systematically measures three core components of memory: immediate memory, working memory, and long-term memory. Results are reported as the Memory Quotient (MQ), where higher MQ values correspond to superior memory capacity. Memory function The Wechsler Memory Scale-Revised for China (WMS-RC) is a standardized and widely implemented instrument for evaluating comprehensive memory function [47]. It systematically measures three core components of memory: immediate memory, working memory, and long-term memory. Results are reported as the Memory Quotient (MQ), where higher MQ values correspond to superior memory capacity. Executive functionThe Victoria Stroop Test (VST), an adaptation of the traditional Stroop paradigm, is designed to evaluate cognitive flexibility and inhibitory control [48]. This test comprises three distinct conditions: identifying the color of dots, naming the color of neutral words, and naming the ink color of incongruent color words. Participants must rapidly recognize and verbalize the correct colors, with the examiner recording the total completion time as an indicator of executive functioning. Executive function The Victoria Stroop Test (VST), an adaptation of the traditional Stroop paradigm, is designed to evaluate cognitive flexibility and inhibitory control [48]. This test comprises three distinct conditions: identifying the color of dots, naming the color of neutral words, and naming the ink color of incongruent color words. Participants must rapidly recognize and verbalize the correct colors, with the examiner recording the total completion time as an indicator of executive functioning. AttentionThe Trail Making Test Part B (TMT-B) is a neuropsychological assessment tool used to measure attention, cognitive flexibility, and visual-motor tracking [49]. Participants are required to alternately connect numbers from 1 to 25, switching between circles and squares in ascending order. The completion time is recorded, with faster performance reflecting higher levels of attentional control and cognitive processing speed. Attention The Trail Making Test Part B (TMT-B) is a neuropsychological assessment tool used to measure attention, cognitive flexibility, and visual-motor tracking [49]. Participants are required to alternately connect numbers from 1 to 25, switching between circles and squares in ascending order. The completion time is recorded, with faster performance reflecting higher levels of attentional control and cognitive processing speed. fNIRSfNIRS signals will be acquired using a multi-channel continuous-wave imaging system (NIRScout, NIRx Medical Technologies LLC, Glen Head, NY, USA). The system operates at dual wavelengths of 780 nm and 830 nm, with a sampling rate of 10 Hz. The source–detector separation will be fixed at 30 mm, yielding a total of 51 measurement channels that cover the frontopolar cortex, DLPFC, premotor cortex, supplementary motor area (SMA), and bilateral temporal lobes. Optode placement will follow the international 10–20 system, with the Cz location used as the reference point prior to cap positioning Three task paradigms will be employed during fNIRS recording, with a total duration of approximately 12 minutes: ① Resting-State task (5 minutes)Participants will be instructed to remain seated, stay awake with their eyes open, and fixate on a centrally displayed cross (“+”).② 2-Back working memory task (5 minutes)A sequence of uppercase letters will be presented on the screen (stimulus duration: 1 s; interstimulus interval: 0.5 s). Participants will be required to determine whether the current letter matches the one presented two trials earlier. If it does, they will respond via a button press; otherwise, no response will be required. The task will consist of six blocks, each comprising a 30-second task period followed by a 20-second rest period. Behavioral data, including accuracy and reaction time, will be recorded.③ Verbal fluency task (2 minutes)This task will include a 30-second pre-task baseline, a 60-second task period, and a 30-second post-task baseline. During baseline periods, participants will be asked to repeatedly count aloud from 1 to 5. During the task period, they will be instructed to generate as many phrases as possible containing a given Chinese character (e.g., “白 [white]”, “北 [north]”, “火 [fire]”). Character cues will be updated every 20 s to minimize silence. The number of valid words and reaction times will be recorded. fNIRS fNIRS signals will be acquired using a multi-channel continuous-wave imaging system (NIRScout, NIRx Medical Technologies LLC, Glen Head, NY, USA). The system operates at dual wavelengths of 780 nm and 830 nm, with a sampling rate of 10 Hz. The source–detector separation will be fixed at 30 mm, yielding a total of 51 measurement channels that cover the frontopolar cortex, DLPFC, premotor cortex, supplementary motor area (SMA), and bilateral temporal lobes. Optode placement will follow the international 10–20 system, with the Cz location used as the reference point prior to cap positioning Three task paradigms will be employed during fNIRS recording, with a total duration of approximately 12 minutes: ① Resting-State task (5 minutes) Participants will be instructed to remain seated, stay awake with their eyes open, and fixate on a centrally displayed cross (“+”). ② 2-Back working memory task (5 minutes) A sequence of uppercase letters will be presented on the screen (stimulus duration: 1 s; interstimulus interval: 0.5 s). Participants will be required to determine whether the current letter matches the one presented two trials earlier. If it does, they will respond via a button press; otherwise, no response will be required. The task will consist of six blocks, each comprising a 30-second task period followed by a 20-second rest period. Behavioral data, including accuracy and reaction time, will be recorded. ③ Verbal fluency task (2 minutes) This task will include a 30-second pre-task baseline, a 60-second task period, and a 30-second post-task baseline. During baseline periods, participants will be asked to repeatedly count aloud from 1 to 5. During the task period, they will be instructed to generate as many phrases as possible containing a given Chinese character (e.g., “白 [white]”, “北 [north]”, “火 [fire]”). Character cues will be updated every 20 s to minimize silence. The number of valid words and reaction times will be recorded. Muscle massMuscle mass will be assessed using bioelectrical impedance analysis (BIA) with the InBody S10 device (InBody Co., Ltd., Seoul, Korea). This device provides a direct measurement of appendicular skeletal muscle mass (ASM), and the ASMI will be calculated using the formula: ASMI (kg/m²) = ASM (kg)/height² (m²). Muscle mass Muscle mass will be assessed using bioelectrical impedance analysis (BIA) with the InBody S10 device (InBody Co., Ltd., Seoul, Korea). This device provides a direct measurement of appendicular skeletal muscle mass (ASM), and the ASMI will be calculated using the formula: ASMI (kg/m²) = ASM (kg)/height² (m²). Knee extension strengthKnee extension strength (KES) will be evaluated using an estimated 1RM test. Due to the potential risk of injury associated with standard 1RM testing in older people [50], a submaximal testing protocol will be applied. Participants will be seated in an extensor chair with a weight plate and will perform knee extensions while maintaining a hip joint angle between 90° and 100° [51, 52]. If more than 10 repetitions are completed at the initial weight, the load will be progressively increased until the participant can perform fewer than 10 repetitions. The final weight at that point will be recorded as the submaximal load, and the estimated 1RM will be calculated using the formula: Estimated 1RM (kg) = submaximal weight (kg)/(1.0278 – maximal repetitions × 0.0278) [53]. Knee extension strength Knee extension strength (KES) will be evaluated using an estimated 1RM test. Due to the potential risk of injury associated with standard 1RM testing in older people [50], a submaximal testing protocol will be applied. Participants will be seated in an extensor chair with a weight plate and will perform knee extensions while maintaining a hip joint angle between 90° and 100° [51, 52]. If more than 10 repetitions are completed at the initial weight, the load will be progressively increased until the participant can perform fewer than 10 repetitions. The final weight at that point will be recorded as the submaximal load, and the estimated 1RM will be calculated using the formula: Estimated 1RM (kg) = submaximal weight (kg)/(1.0278 – maximal repetitions × 0.0278) [53]. Physical performanceIn accordance with the AWGS 2019 guidelines [54], physical performance will be evaluated using the Short Physical Performance Battery (SPPB) and the 6-meter walk test. The SPPB comprises three components: a standing balance test, a 4-meter walk test, and a chair sit-to-stand test [55]. Each component is scored on a scale from 0 to 4, with higher scores indicating better physical performance [56]. The standing balance test evaluates the participant’s ability to maintain stability in three increasingly difficult stances—side-by-side, semi-tandem, and tandem. The 4-meter walk test measures the time taken to walk a 4-meter distance at a normal pace, and the shorter time of two trials is recorded. In the chair sit-to-stand test, participants cross their arms over their chest and perform five repetitions of standing up and sitting down as quickly as possible. The total time is recorded from the initial seated position to the completion of the fifth stand-up and sit-down repetition.For the 6-meter walk test, participants will walk a 6-meter distance at their usual pace, and the time taken will be recorded to assess gait speed. Physical performance In accordance with the AWGS 2019 guidelines [54], physical performance will be evaluated using the Short Physical Performance Battery (SPPB) and the 6-meter walk test. The SPPB comprises three components: a standing balance test, a 4-meter walk test, and a chair sit-to-stand test [55]. Each component is scored on a scale from 0 to 4, with higher scores indicating better physical performance [56]. The standing balance test evaluates the participant’s ability to maintain stability in three increasingly difficult stances—side-by-side, semi-tandem, and tandem. The 4-meter walk test measures the time taken to walk a 4-meter distance at a normal pace, and the shorter time of two trials is recorded. In the chair sit-to-stand test, participants cross their arms over their chest and perform five repetitions of standing up and sitting down as quickly as possible. The total time is recorded from the initial seated position to the completion of the fifth stand-up and sit-down repetition. For the 6-meter walk test, participants will walk a 6-meter distance at their usual pace, and the time taken will be recorded to assess gait speed. DepressionThe GDS-15 is a widely used screening instrument for assessing depressive symptoms in older people. The total score ranges from 0 to 15, with higher scores indicating greater symptom severity. A score of 5 or higher suggests the presence of depressive symptoms, while a score of 10 or more generally indicates more severe symptoms, warranting further clinical assessment. Depression The GDS-15 is a widely used screening instrument for assessing depressive symptoms in older people. The total score ranges from 0 to 15, with higher scores indicating greater symptom severity. A score of 5 or higher suggests the presence of depressive symptoms, while a score of 10 or more generally indicates more severe symptoms, warranting further clinical assessment. Statistical analysis Clinical data analysis Statistical analyses will be performed using MATLAB and SPSS version 27.0 (IBM Inc., Chicago, IL, USA). Descriptive statistics will summarize the data as follows: normally distributed data will be expressed as mean ± SD, non-normally distributed data as median and interquartile range (IQR), and categorical data as frequencies (n) and percentages (%). Group comparisons will be conducted using appropriate statistical tests: one-way analysis of variance (ANOVA) for normally distributed data, the Kruskal-Wallis H-test for non-normally distributed data, and chi-square tests for categorical data. Time effects will be assessed by analyzing changes in data across baseline, post-intervention, and follow-up time points using Repeated Measures ANOVA (RM-ANOVA), following the intention-to-treat principle. Missing data will be assumed to be missing at random (MAR) and will be addressed using standard maximum likelihood estimation. To adjust for multiple comparisons, a false discovery rate (FDR) correction will be applied to the p-values, with statistical significance defined as an FDR-adjusted p-value < 0.05. fNIRS data analysis Preprocessing of the fNIRS signals will be conducted using MATLAB (Version R2017a, MathWorks, Natick, MA, USA) in conjunction with the open-source package Homer 2.0 [57]. Preprocessing steps will include artifact removal, signal conversion, and band-pass filtering. The processed data will be converted into hemoglobin concentration changes (hemoglobin oxygenated, HbO, and hemoglobin deoxygenated, HbR), with HbO serving as the primary measure for cortical activation across all channels. Statistical analyses will consist of the following components: Activation AnalysisRM-ANOVA will be employed to compare HbO changes among the three groups under both resting-state and task conditions. The analyses will be conducted at three time points: baseline, post-intervention, and follow-up, to assess the main effects of time, group, and their interaction (time × group). Activation Analysis RM-ANOVA will be employed to compare HbO changes among the three groups under both resting-state and task conditions. The analyses will be conducted at three time points: baseline, post-intervention, and follow-up, to assess the main effects of time, group, and their interaction (time × group). Functional Connectivity AnalysisSpearman correlation analysis will be applied to evaluate changes in functional connectivity between the prefrontal and temporal cortices, based on the correlation coefficients of HbO time-series signals from the relevant channels. Functional Connectivity Analysis Spearman correlation analysis will be applied to evaluate changes in functional connectivity between the prefrontal and temporal cortices, based on the correlation coefficients of HbO time-series signals from the relevant channels. Behavior–Brain Coupling AnalysisTo explore the relationship between behavioral outcomes and neural activity, Spearman correlation analysis will be used to examine associations between task performance and task-evoked HbO changes in the prefrontal and temporal regions, thereby quantifying the degree of behavior–brain coupling. Behavior–Brain Coupling Analysis To explore the relationship between behavioral outcomes and neural activity, Spearman correlation analysis will be used to examine associations between task performance and task-evoked HbO changes in the prefrontal and temporal regions, thereby quantifying the degree of behavior–brain coupling. Adverse events monitoring and reporting Prior to the intervention, participants will undergo fall prevention education and a comprehensive pre-exercise assessment, which will include evaluation of their cardiovascular, metabolic, and renal health history, exercise habits, and any musculoskeletal or joint pain. Additionally, the scalp of each participant will be examined to ensure the absence of trauma or dermatological conditions. During the intervention, participants will receive continuous supervision and professional guidance to minimize the risk of injury. The intensity of rTMS stimulation will be tailored to each participant’s individual tolerance, based on the pre-assessment and ongoing monitoring throughout the intervention. All adverse events occurring during the study will be meticulously documented and evaluated by a medical professional to determine their potential association with the intervention. Any adverse events related to the intervention will be promptly reported to the local ethics committee, and appropriate management strategies will be explored in collaboration. Participants will retain the right to withdraw from the study at any point during the intervention period. Patient and public involvement Public involvement in this study will begin during the recruitment phase, utilizing a variety of strategies, including annual community health check-ups, educational seminars, home visits, and public announcements via bulletin boards. At the conclusion of the follow-up period, individual study results will be provided to each participant. Although participants will not be directly involved in the study design, they will receive comprehensive information regarding the time commitments and study requirements prior to the intervention. Only participants who voluntarily agree to participate, after being fully informed, will be asked to sign an informed consent form. Data management and monitoring The study will utilize Microsoft Excel 365 for the recording and storage of all relevant data, including socio-demographic characteristics, outcome measurements, and adverse events. To ensure participant confidentiality, all electronic data will be encrypted, and participant names will be replaced with numerical identifiers. All data will be validated through double-data entry (manual data entry performed by two blinded data-entry clerks) and by applying validation rules, range checks, logic checks, and duplicate record checks for all quantitative and categorical variables [58]. A Data Monitoring Committee (DMC), comprising independent clinical experts, researchers, trialists, and statisticians, will regularly monitor study progress, data quality, and participant safety. The DMC will review adverse events and protocol adherence at scheduled intervals and provide recommendations if safety or data integrity concerns arise [59]. To ensure data integrity, both paper-based and electronic data will be destroyed after a retention period of five years. Ethics and dissemination This study adheres to the principles outlined in the Declaration of Helsinki. The research protocol was approved by the Ethical Committee of Chongming Hospital, affiliated with Shanghai University of Medicine and Health Sciences, in January 2025 (Approval No. CMEC-2025-KT-02) and has been registered with the International Traditional Medicine Clinical Trial Registry under registration number ITMCTR2025000311, on February 17, 2025. Written informed consent will be obtained from all participants prior to their involvement in the study. Data collected from participants will include socio-demographic characteristics, clinical parameters, and monitoring indicators. Participants will be required to provide signed informed consent. All paper-based data will be stored securely in the project office, and electronic data will be encrypted and archived on computers at Chongming Hospital, affiliated with Shanghai University of Medicine and Health Sciences. Any modifications or updates to the study will be promptly reported and updated at the International Traditional Medicine Clinical Trial Registry. Discussion To the best of our knowledge, this study will be the first RCT to investigate the combined effects of multicomponent exercise and rTMS in older people diagnosed with both sarcopenia and MCI. Sarcopenia and CI are leading contributors to disability in older people, significantly diminishing their quality of life and imposing a considerable burden on healthcare systems and society. This study is designed to concurrently enhance physical performance and cognitive function, thereby promoting overall health and functional independence in the aging population. This study will have several key strengths. Firstly, it will use an integrated approach targeting the concurrent decline in both cognitive and physical functions. Sarcopenia and MCI are both prevalent degenerative conditions in older people, with mutual pathological interactions. Sarcopenia accelerates cognitive decline through mechanisms such as chronic inflammation, mitochondrial dysfunction, and disruption of the muscle–brain axis [60, 61]. Conversely, cognitive impairment impairs motor planning and daily function, exacerbating muscle loss and physical decline [62, 63]. This bidirectional relationship can lead to a vicious cycle of functional deterioration. Although most previous studies have focused on interventions targeting these conditions separately, this study will treat sarcopenia and MCI as a unified entity, offering a novel pathway for preventing and managing geriatric syndromes. Secondly, this study will propose a combined intervention of physical exercise and rTMS to synergistically modulate both central and peripheral systems, thereby optimizing therapeutic outcomes. Exercise facilitates neuroplasticity and remodels to enhance cognitive function [64]. In addition, it improves muscle strength, increases metabolic rate, and reduces inflammation, thereby addressing sarcopenia [30]. However, the neuroplastic effects of exercise develop gradually and are primarily mediated through indirect mechanisms [65]. In contrast, rTMS directly modulates cortical excitability, leading to significant improvements in cognitive functions such as executive function and attention [66]. Emerging evidence also suggests that rTMS may mitigate sarcopenia by reducing neuroinflammation, suppressing oxidative stress, and enhancing neuromuscular conduction [16]. Thus, exercise optimizes peripheral physiological conditions, supporting the central plasticity induced by rTMS, while rTMS further amplifies the cognitive and physical function benefits of exercise. The synergistic integration of these two interventions is anticipated to yield superior results in counteracting both cognitive and physical decline, surpassing the efficacy of single intervention [39, 67]. Thirdly, this study will employ rTMS targeting the left DLPFC, selected for its dual involvement in cognitive and motor regulation. Previous studies have demonstrated that the DLPFC participates in higher-order cognitive processes, including executive control, goal-directed behavior, and motivation [68, 69], which are key psychological mechanisms underlying physical activity. Dysfunction in this region is often associated with apathy, reduced motivation, and diminished engagement [70], all of which are recognized as major risk factors for sarcopenia in older people. Although the motor regulatory function of the DLPFC has been less extensively investigated, existing evidence suggests that it exerts top-down modulation of motor output through its functional connectivity with M1 [71, 72]. Moreover, as a key node linking the default mode, attentional, and motor networks [73], the DLPFC may facilitate the coordination and integration of cognitive control processes—such as movement attention and error correction—with motor performance. Previous studies have also reported that high-frequency rTMS applied to the DLPFC can significantly improve lower-limb motor function, gait speed, and postural stability [74, 75]. Therefore, this study will target the left DLPFC to concurrently modulate cognitive and motor functions, aiming to achieve improvements in both cognitive impairment and sarcopenia. Fourth, this study will not only evaluate the efficacy of cognitive improvement but also investigate its underlying neural mechanisms. fNIRS will be used to dynamically monitor changes in HbO levels and functional connectivity in key cortical regions [76]. Cognitive function will be systematically assessed using standardized neuropsychological tools, including MoCA, WMS-RC, VST, and TMT-B. By integrating neurophysiological indicators with behavioral outcomes, the study aims to elucidate the neural mechanisms through which combined rTMS and exercise interventions promote cognitive improvement in aging individuals. However, this study will also have certain limitations. Firstly, the multicomponent intervention may require a longer duration, which could affect participant adherence and motivation [77, 78], particularly among older adults with sarcopenia [1] and MCI [79], who often experience poor physical health. To improve adherence, attendance will be recorded, make-up sessions will be provided for missed classes, and professional coaches will offer continuous guidance to help participants stay on track and maintain high compliance. Secondly, although Baduanjin involves only eight postures and is relatively simple compared to other exercises [80], it may still be challenging for older individuals with sarcopenia and MCI. Cognitive decline can impair memory and imitation abilities [81, 82], while sarcopenia is often associated with balance dysfunction [83], both of which may hinder correct performance. To ensure standardization, professional coaches with over five years of Baduanjin teaching experience will provide pre-intervention training, and offer ongoing demonstrations, supervision, and corrections throughout the intervention. Supplementary Information Supplementary Material 1. Supplementary Material 2. Abbreviations Mild Cognitive Impairment Alzheimer’s Disease Brain-Derived Neurotrophic Factor Insulin-Like Growth Factor-1 Repetitive Transcranial Magnetic Stimulation The Multicomponent Exercise with Active rTMS The Multicomponent Exercise with Sham rTMS Functional Near-Infrared Spectroscopy International Physical Activity Questionnaire Food Frequency Questionnaire Asian Working Group for Sarcopenia 2019 Criteria Appendicular Skeletal Muscle Mass Index Handgrip Strength Gait Speed Standard Deviation Geriatric Depression Scale-15 Transcranial Direct Current Stimulation Strength, Assistance with Walking, Rise from a Chair, Climb Stairs, and Falls Mini-Mental State Examination One-Repetition Maximum Rating of Perceived Exertion Resting Motor Threshold Primary Motor Cortex Motor Evoked Potentials Dorsolateral Prefrontal Cortex Montreal Cognitive Assessment Wechsler Memory Scale-Revised for China Memory Quotient Victoria Stroop Test Trail Making Test Part B Supplementary Motor Area Bioelectrical Impedance Analysis Appendicular Skeletal Muscle Mass Knee Extension Strength Short Physical Performance Battery Interquartile Range Repeated Measures Analysis of Variance Missing at Random False Discovery Rate Data Monitoring Committee Default Mode Network Hemoglobin Oxygenated Hemoglobin Deoxygenated Long-term Potentiation Authors’ contributions YR, XH and ZZ contributed equally to this study. All authors conceptualised the study and designed methodology. YR, XH and ZZ drafted the original draft. MZ and GY contributed to data analysis and manuscript revision. LH and NC provided the leadership and supervision into the protocol, verified the validation of the trial design and provided a review of this manuscript. All authors approved the publication of this protocol. Funding This work was supported by the Shanghai “Rising Stars of Medical Talent” Youth Development Program for Outstanding Youth Medical Talents (No. SHWSRS2025-71); the Research Projects of Shanghai Municipal Health Commission, “Research on early screening and intervention strategies for cognitive impairment in community-dwelling older people with sarcopenia” (No. 20254Z0006); the Research Projects of Shanghai Municipal Center for Disease Control and Prevention and Shanghai Municipal Health Commission, “Impact of multidisciplinary role collaboration within family doctor teams on functional improvement in older patients with sarcopenia: a randomized controlled study based on the Shanghai ‘General Practitioner–Specialist–Family’ integrated model” (No. 2025JZ41); and the Research Projects of Shanghai University of Medicine and Health Sciences, “Research on an intelligent community-based sarcopenia screening system based on multimodal spatiotemporal biomechanical decoupling” (No. XJJJ2503-1). The study protocol did not undergo independent peer review as part of the funding approval process. The funders were not involved in study design and will not participate in data analysis, interpretation, or publication decisions. Data availability The datasets generated during this study will be available from the corresponding author on reasonable request. Declarations Ethics approval and consent to participate The study was approved by the Ethical Committee of Chongming Hospital Affiliated to Shanghai University of Medicine and Health Sciences in January 2025, (Approval No. CMEC-2025-KT-02, 2025.1.17). This study was registered on the International Traditional Medicine Clinical Trial Registry (registration number ITMCTR2025000311) on February 17, 2025. All participants will provide written informed consent before participating in the study. The study was conducted in accordance with the Declaration of Helsinki. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Yanqing Ren, Xiangfeng He and Zhen Zhang contributed equally to this study. Contributor Information Lingyan Huang, Email: alice37yn@163.com. Nan Chen, Email: chennanreh2020@126.com. References Associated Data Supplementary Materials Supplementary Material 1. Supplementary Material 2. Data Availability Statement The datasets generated during this study will be available from the corresponding author on reasonable request.